Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA approves Yuvezzi, first fixed-dose eye drop for presbyopia, offering non-invasive vision improvement.
The FDA has approved Yuvezzi, a daily eye drop combining carbachol and brimonidine tartrate, as the first fixed-dose treatment for presbyopia, a common age-related near-vision loss affecting millions.
The medication works by creating a pinhole effect through pupil constriction, improving both near and distance vision for up to 8 hours.
Approval was based on two Phase 3 trials showing significant near vision improvement with no serious safety issues over 72,000 treatment days.
Common side effects include headache, eye irritation, and temporary blurred vision.
The drug, expected to launch in the second quarter of 2026, offers a non-invasive alternative to glasses or surgery.
La FDA aprueba Yuvezzi, la primera gota ocular de dosis fija para presbicia, que ofrece una mejora de la visión no invasiva.